Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ADPT | Common Stock | Award | $0 | +85.7K | +117.62% | $0.00 | 159K | Mar 6, 2023 | Direct | |
transaction | ADPT | Common Stock | Sale | -$47.1K | -5.49K | -3.46% | $8.57 | 153K | Mar 6, 2023 | Direct | F1 |
transaction | ADPT | Common Stock | Sale | -$115K | -13.4K | -8.75% | $8.60 | 140K | Mar 7, 2023 | Direct | F2, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ADPT | Stock Option (right to buy) | Award | $0 | +129K | $0.00 | 129K | Mar 6, 2023 | Common Stock | 129K | $8.46 | Direct | F4 |
Id | Content |
---|---|
F1 | This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
F2 | The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2022. |
F3 | The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
F4 | The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |